Ovid Therapeutics Inc.
Use of gaboxadol in the treatment of diabetes and related conditions
Last updated:
Abstract:
Methods and compositions for treating a metabolic disease include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease. In embodiments, administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease is effective to lower one or more of HbA1c level, fasting plasma glucose level, 2-hour oral glucose tolerance test (OGTT) result level, and random plasma glucose level. Gaboxadol or a pharmaceutically acceptable salt thereof may optionally be administered in combination with a hypoglycemic agent.
Status:
Grant
Type:
Utility
Filling date:
8 Oct 2020
Issue date:
5 Apr 2022